Immunomedics Announces Preclinical Study Showed Epratuzumab's B-Cell Modulation Effect Elucidated

by Benzinga Staff
December 10, 2012 8:40 AM | 18 seconds read | Make a Comment

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

Immunomedics, Inc. (Nasdaq: IMMU), abiopharmaceutical company primarily focused on the development of monoclonalantibody-based products for the targeted treatment of cancer, autoimmune andother serious diseases, today reported that its lead antibody drug candidate,epratuzumab, has a distinct way of reducing the immune response of B cells,which, in an autoimmune disease such as lupus, are responsible for producingantibodies that attack the patient's own body.

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: NewsFDA

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.